본문 바로가기
KERD
논문KCI 등재

Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: review of recent studies and recommendations

Peter Van Dael
한국영양학회 (The Korean Nutrition Society)|2021.04|Nutrition Research and Practice|제15권 제2호|pp. 137-159|DOI 10.4162/nrp.2021.15.2.137

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

pregnancyadultbrainheartinfantDocosahexaenoic acideicosapentaenoic acid

초록

Long-chain (LC) n-3 polyunsaturated fatty acids (n-3 PUFAs), in particular docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are nutrients involved in many metabolic and physiological processes, and are referred to as n-3 LCPUFA. They have been extensively studied for their effects in human nutrition and health. This paper provides an overview on metabolism, sources, dietary intake, and status of n-3 LCPUFA. A summary of the dietary recommendations for n-3 LCPUFAs for different age groups as well as specific physiological conditions is provided. Evidence for n-3 LCPUFA in cardiovascular diseases, including new studies, is reviewed. Expert recommendations generally support a beneficial effect of n-3 LCPUFA on cardiovascular health and recommend a daily intake of 500 mg as DHA and EPA, or 1–2 servings of fish per week. The role of n-3 LCPUFA on brain health, in particular neurodegenerative disorders and depression, is reviewed. The evidence for beneficial effects of n-3 LCPUFA on neurodegenerative disorders is non-conclusive despite mechanistic support and observational data. Hence, no definite n-3 LCPUFA expert recommendations are made. Data for the beneficial effect of n-3 LCPUFA on depression are generally compelling. Expert recommendations have been established: 200–300 mg/day for depression; up to 1–2 g/day for major depressive disorder. Recent studies support a beneficial role of n-3 LCPUFAs in reducing the risk for premature birth, with a daily intake of 600–800 mg of DHA during pregnancy. Finally, international experts recently reviewed the scientific evidence on DHA and arachidonic acid (ARA) in infant nutrition and concluded that the totality of data support that infant and follow-on formulas should provide both DHA and ARA at levels similar to those in breast milk. In conclusion, the available scientific data support that dietary recommendations for n-3 LCPUFA should be established for the general population and for subjects with specific physiological conditions.

Abstract

Long-chain (LC) n-3 polyunsaturated fatty acids (n-3 PUFAs), in particular docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are nutrients involved in many metabolic and physiological processes, and are referred to as n-3 LCPUFA. They have been extensively studied for their effects in human nutrition and health. This paper provides an overview on metabolism, sources, dietary intake, and status of n-3 LCPUFA. A summary of the dietary recommendations for n-3 LCPUFAs for different age groups as well as specific physiological conditions is provided. Evidence for n-3 LCPUFA in cardiovascular diseases, including new studies, is reviewed. Expert recommendations generally support a beneficial effect of n-3 LCPUFA on cardiovascular health and recommend a daily intake of 500 mg as DHA and EPA, or 1–2 servings of fish per week. The role of n-3 LCPUFA on brain health, in particular neurodegenerative disorders and depression, is reviewed. The evidence for beneficial effects of n-3 LCPUFA on neurodegenerative disorders is non-conclusive despite mechanistic support and observational data. Hence, no definite n-3 LCPUFA expert recommendations are made. Data for the beneficial effect of n-3 LCPUFA on depression are generally compelling. Expert recommendations have been established: 200–300 mg/day for depression; up to 1–2 g/day for major depressive disorder. Recent studies support a beneficial role of n-3 LCPUFAs in reducing the risk for premature birth, with a daily intake of 600–800 mg of DHA during pregnancy. Finally, international experts recently reviewed the scientific evidence on DHA and arachidonic acid (ARA) in infant nutrition and concluded that the totality of data support that infant and follow-on formulas should provide both DHA and ARA at levels similar to those in breast milk. In conclusion, the available scientific data support that dietary recommendations for n-3 LCPUFA should be established for the general population and for subjects with specific physiological conditions.

참고문헌 (134)

  1. Global Status Report on Noncommunicable Diseases, "World Health Organization", WHO, ~ (2014)
  2. "Global Action Plan for the Prevention and Control of NCDs 2013–2020" (2013)[URL]
  3. Mozaffarian D, "Omega-3 fatty acids and cardiovascular disease : effects on risk factors, molecular pathways, and clinical events", J Am Coll Cardiol, 58, pp.2047~2067 (2011)
  4. Sinn N, "Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial", Br J Nutr, 107, pp.1682~1693 (2012)
  5. Middleton P, "Omega-3 fatty acid addition during pregnancy", Cochrane Database Syst Rev, 11, pp.CD003402~ (2018)
  6. Lapillonne A, "Enteral and parenteral lipid requirements of preterm infants", World Rev Nutr Diet, 110, pp.82~98 (2014)
  7. Koletzko B, "Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation", Am J Clin Nutr, 111, pp.10~16 (2020)
  8. Goyens PL, "Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio", Am J Clin Nutr, 84, pp.44~53 (2006)
  9. Kinsella JE, "Dietary polyunsaturated fatty acids and eicosanoids : potential effects on the modulation of inflammatory and immune cells : an overview", Nutrition, 6, pp.24~44 (1990)
  10. Clandinin MT, "Brain development and assessing the supply of polyunsaturated fatty acid", Lipids, 34, pp.131~137 (1999)
  11. Salem N Jr, "Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants", Proc Natl Acad Sci U S A, 93, pp.49~54 (1996)
  12. Schaeffer L, "Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids", Hum Mol Genet, 15, pp.1745~1756 (2006)
  13. Micha R, "Mozaffarian DGlobal Burden of Diseases Nutrition and Chronic Diseases Expert Group NutriCoDE. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys", BMJ, 348, pp.g2272~ (2014)
  14. Patterson AC, "Biomarker and dietary validation of a Canadian food frequency questionnaire to measure eicosapentaenoic and docosahexaenoic acid intakes from whole food, functional food, and nutraceutical sources", J Acad Nutr Diet, 112, pp.1005~1014 (2012)
  15. Fratesi JA, "Direct quantitation of omega-3 fatty acid intake of Canadian residents of a long-term care facility", Appl Physiol Nutr Metab, 34, pp.1~9 (2009)
  16. Patterson AC, "The percentage of DHA in erythrocytes can detect non-adherence to advice to increase EPA and DHA intakes", Br J Nutr, 111, pp.270~278 (2014)
  17. Block RC, "Determinants of blood cell omega-3 fatty acid content", Open Biomark J, 1, pp.1~6 (2008)
  18. Flock MR, "Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial", J Am Heart Assoc, 2, pp.e000513~ (2013)
  19. Stark KD, "Alcohol consumption in pregnant, black women is associated with decreased plasma and erythrocyte docosahexaenoic acid", Alcohol Clin Exp Res, 29, pp.130~140 (2005)
  20. Harris WS, "Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study", Atherosclerosis, 225, pp.425~431 (2012)
  21. Crowe FL, "Serum n-3 long-chain PUFA differ by sex and age in a population-based survey of New Zealand adolescents and adults", Br J Nutr, 99, pp.168~174 (2008)
  22. Siscovick DS, "Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest", JAMA, 274, pp.1363~1367 (1995)
  23. Albert CM, "Blood levels of long-chain n-3 fatty acids and the risk of sudden death", N Engl J Med, 346, pp.1113~1118 (2002)
  24. Schaefer EJ, "Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease : the Framingham Heart Study", Arch Neurol, 63, pp.1545~1550 (2006)
  25. Stark KD, "Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults", Prog Lipid Res, 63, pp.132~152 (2016)
  26. FAO Fats and Fatty Acids in Human Nutrition. Report of an Expert Consultation, "Food and Agriculture Organization of the United Nations", Food and Agriculture Organization of the United Nations, ~ (2010)
  27. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), "Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol", EFSA J, 8, pp.1461~ (2010)
  28. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), "Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)", EFSA J, 10, pp.2815~ (2012)
  29. Institute of Medicine (US), "Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids" (2005), National Academy Press
  30. "Advice about Eating Fish" (2020)[URL]
  31. "Qualified Health Claims: Letters of Enforcement Discretion" (2020)[URL]
  32. U.S. Department of Health and Human Services, "2015–2020 Dietary Guidelines for Americans" (2020), U.S. Government Printing Office
  33. Scientific Report of the 2015 Dietary Guidelines Advisory Committee, "US Department of Agriculture", U.S. Government Printing Office, ~ (2015)
  34. National Health and Medical Research Council (AU), "Nutrient Reference Values for Australia and New Zealand including Recommended Dietary Intakes (version 1.2)" (2017), National Health and Medical Research Council (AU)
  35. Dolecek TA, "Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial", Proc Soc Exp Biol Med, 200, pp.177~182 (1992)
  36. Iso H, "Intake of fish and omega-3 fatty acids and risk of stroke in women", JAMA, 285, pp.304~312 (2001)
  37. "Substances affirmed as generally recognized as safe: menhaden oil" (2005)[URL]
  38. "Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report" (2011)[URL]
  39. Beaufrère B, "Recommended Nutritional Intakes for the French Population" (2001), Tec et Doc
  40. Mozaffarian D, "(n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?", J Nutr, 142, pp.614S~625S (2012)
  41. Kris-Etherton PM, "Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease", Circulation, 106, pp.2747~2757 (2002)
  42. Siscovick DS, "Mozaffarian DAmerican Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic HealthCouncil on Epidemiology and Prevention on Cardiovascular Disease in the YoungCouncil on Cardiovascular and Stroke NursingCouncil on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association", Circulation, 135, pp.e867~e884 (2017)
  43. Skulas-Ray AC, "Thrombosis and Vascular BiologyCouncil on Lifestyle and Cardiometabolic HealthCardiovascular Disease in the YoungCouncil on Cardiovascular and Stroke NursingCouncil on Clinical Cardiology. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association", Circulation, 140, pp.e673~e691 (2019)
  44. Aung T, "Clarke ROmega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77,917 individuals", JAMA Cardiol, 3, pp.225~234 (2018)
  45. Abdelhamid AS, "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease", Cochrane Database Syst Rev, 7, pp.CD003177~ (2018)
  46. Arca M, "Hypertriglyceridemia and omega-3 fatty acids : Their often overlooked role in cardiovascular disease prevention", Nutr Metab Cardiovasc Dis, 28, pp.197~205 (2018)
  47. Rimm EB, "Lichtenstein AHAmerican Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic HealthCouncil on Epidemiology and PreventionCouncil on Cardiovascular Disease in the YoungCouncil on Cardiovascular and Stroke NursingCouncil on Clinical Cardiology. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association", Circulation, 138, pp.e35~e47 (2018)
  48. Pizzini A, "The role of omega-3 fatty acids in the setting of coronary artery disease and COPD : a review", Nutrients, 10, pp.1864~ (2018)
  49. Wen YT, "Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease : a meta-analysis of randomized controlled trials", Nutr Metab Cardiovasc Dis, 24, pp.470~475 (2014)
  50. Kwak SM, "Efficacy of omega-3 fatty acid supplements(eicosapentaenoic acid and docosahexaenoic acid)in the secondary prevention of cardiovascular disease : a meta-analysis of randomized, double-blind, placebo-controlled trials", Arch Intern Med, 172, pp.686~694 (2012)
  51. Nestel P, "Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease", Heart Lung Circ, 24, pp.769~779 (2015)
  52. Meyer BJ, "Effects of omega-3 long chain polyunsaturated fatty acid supplementation on cardiovascular mortality : the importance of the dose of DHA", Nutrients, 9, pp.1305~ (2017)
  53. Manson JE, "Marine n−3 fatty acids and prevention of cardiovascular disease and cancer", N Engl J Med, 380, pp.23~32 (2019)
  54. Bhatt DL, "Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia", N Engl J Med, 380, pp.11~22 (2019)
  55. Uauy R, "Essential fatty acids in visual and brain development", Lipids, 36, pp.885~895 (2001)
  56. Uauy R, "Essential fatty acids in early life : structural and functional role", Proc Nutr Soc, 59, pp.3~15 (2000)
  57. Carlson SE, "Docosahexaenoic acid and arachidonic acid nutrition in early development", Adv Pediatr, 63, pp.453~471 (2016)
  58. Makrides M, "Long-chain polyunsaturated fatty acid requirements during pregnancy and lactation", Am J Clin Nutr, 71, pp.307S~311S (2000)
  59. Sattar N, "Essential fatty acids in relation to pregnancy complications and fetal development", Br J Obstet Gynaecol, 105, pp.1248~1255 (1998)
  60. Cansev M, "Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses", Alzheimers Dement, 4, pp.S153~S168 (2008)
  61. Beltz BS, "Omega-3 fatty acids upregulate adult neurogenesis", Neurosci Lett, 415, pp.154~158 (2007)
  62. Kawakita E, "Docosahexaenoic acid promotes neurogenesis in vitro and in vivo", Neuroscience, 139, pp.991~997 (2006)
  63. Cutuli D, "Functional and structural benefits induced by omega-3 polyunsaturated fatty acids during aging", Curr Neuropharmacol, 15, pp.534~542 (2017)
  64. Aryal S, "Omega-3 fatty acids regulate plasticity in distinct hippocampal glutamatergic synapses", Eur J Neurosci, 49, pp.40~50 (2019)
  65. Castro-Gómez P, "Relevance of dietary glycerophospholipids and sphingolipids to human health", Prostaglandins Leukot Essent Fatty Acids, 101, pp.41~51 (2015)
  66. Cardoso C, "Dietary DHA and health : cognitive function ageing", Nutr Res Rev, 29, pp.281~294 (2016)
  67. Calviello G, "Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators : their potential role in inflammatory, neurodegenerative, and neoplastic diseases", Biomed Res Int, 2013, pp.743171~ (2013)
  68. Moore K, "Diet, nutrition and the ageing brain : current evidence and new directions", Proc Nutr Soc, 77, pp.152~163 (2018)
  69. Yassine HN, "Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ε4 carriers : a review", JAMA Neurol, 74, pp.339~347 (2017)
  70. Butler M, "Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia : a systematic review", Ann Intern Med, 168, pp.52~62 (2018)
  71. Burckhardt M, "Omega-3 fatty acids for the treatment of dementia", Cochrane Database Syst Rev, 4, pp.CD009002~ (2016)
  72. Dangour AD, "B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia : a systematic review", J Alzheimers Dis, 22, pp.205~224 (2010)
  73. Sydenham E, "Omega 3 fatty acid for the prevention of cognitive decline and dementia", Cochrane Database Syst Rev, 6, pp.CD005379~ (2012)
  74. Chew EY, "Effect of omega-3 fatty acids, lutein", zeaxanthin, or other nutrient supplementation on cognitive function : the AREDS2 randomized clinical trial, 2015, pp.314, 791~801
  75. Tully AM, "Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease : a case-control study", Br J Nutr, 89, pp.483~489 (2003)
  76. Yassine HN, "Association of serum docosahexaenoic acid with cerebral amyloidosis", JAMA Neurol, 73, pp.1208~1216 (2016)
  77. van Gelder BM, "Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men : the Zutphen Elderly Study", Am J Clin Nutr, 85, pp.1142~1147 (2007)
  78. Kalmijn S, "Dietary fat intake and the risk of incident dementia in the Rotterdam Study", Ann Neurol, 42, pp.776~782 (1997)
  79. Engelhart MJ, "Diet and risk of dementia : Does fat matter? : the Rotterdam Study", Neurology, 59, pp.1915~1921 (2002)
  80. Pottala JV, "Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes : WHIMS-MRI study", Neurology, 82, pp.435~442 (2014)
  81. Tan ZS, "Red blood cell ω-3 fatty acid levels and markers of accelerated brain aging", Neurology, 78, pp.658~664 (2012)
  82. Zhang Y, "Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks : a dose-response meta-analysis of 21 cohort studies", Am J Clin Nutr, 103, pp.330~340 (2016)
  83. Dangour AD, "Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people : a randomized, double-blind, controlled trial", Am J Clin Nutr, 91, pp.1725~1732 (2010)
  84. Quinn JF, "Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease : a randomized trial", JAMA, 304, pp.1903~1911 (2010)
  85. Freund-Levi Y, "Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease : OmegAD study : a randomized double-blind trial", Arch Neurol, 63, pp.1402~1408 (2006)
  86. Lee LK, "Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment(MCI) : a 12-month randomised, double-blind, placebo-controlled trial", Psychopharmacology(Berl), 225, pp.605~612 (2013)
  87. Jiao J, "Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age : a systematic review and meta-analysis of randomized controlled trials", Am J Clin Nutr, 100, pp.1422~1436 (2014)
  88. Yurko-Mauro K, "Docosahexaenoic acid and adult memory: a systematic review and meta-analysis", PLoS One, 10, pp.e0120391~ (2015)
  89. Mazereeuw G, "Effects of ω-3 fatty acids on cognitive performance: a meta-analysis", Neurobiol Aging, 33, pp.1482.e17~1482.e29 (2012)
  90. Avallone R, "Omega-3 fatty acids and neurodegenerative diseases : new evidence in clinical trials", Int J Mol Sci, 20, pp.4256~ (2019)
  91. Belmaker RH, "Major depressive disorder", N Engl J Med, 358, pp.55~68 (2008)
  92. Murray CJ, "Global mortality, disability, and the contribution of risk factors : Global Burden of Disease Study", Lancet, 349, pp.1436~1442 (1997)
  93. Cipriani A, "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder : a systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
  94. Hibbeln JR, "Healthy intakes of n-3 and n-6 fatty acids : estimations considering worldwide diversity", Am J Clin Nutr, 83, pp.1483S~1493S (2006)
  95. Connor WE, "Importance of n-3 fatty acids in health and disease", Am J Clin Nutr, 71, pp.171S~175S (2000)
  96. Su KP, "Biological mechanism of antidepressant effect of omega-3 fatty acids : how does fish oil act as a ‘mind-body interface’?", Neurosignals, 17, pp.144~152 (2009)
  97. Su KP, "Effects of polyunsaturated fatty acids on psychiatric disorders", Am J Clin Nutr, 72, pp.1241~ (2000)
  98. Lin PY, "A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression", Biol Psychiatry, 68, pp.140~147 (2010)
  99. Hibbeln JR, "Fish consumption and major depression", Lancet, 351, pp.1213~ (1998)
  100. Nemets B, "Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder", Am J Psychiatry, 159, pp.477~479 (2002)
  101. Peet M, "A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs", Arch Gen Psychiatry, 59, pp.913~919 (2002)
  102. Su KP, "Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial", Eur Neuropsychopharmacol, 13, pp.267~271 (2003)
  103. Jazayeri S, "Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder", Aust N Z J Psychiatry, 42, pp.192~198 (2008)
  104. Su KP, "Omega-3 fatty acids for major depressive disorder during pregnancy : results from a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 69, pp.644~651 (2008)
  105. Frangou S, "Efficacy of ethyl-eicosapentaenoic acid in bipolar depression : randomised double-blind placebo-controlled study", Br J Psychiatry, 188, pp.46~50 (2006)
  106. da Silva TM, "Depression in Parkinson's disease : a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation", J Affect Disord, 111, pp.351~359 (2008)
  107. Mischoulon D, "A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder", J Clin Psychiatry, 70, pp.1636~1644 (2009)
  108. Rapaport MH, "Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder : a proof-of-concept study", Mol Psychiatry, 21, pp.71~79 (2016)
  109. Lespérance F, "The efficacy of omega-3 supplementation for major depression : a randomized controlled trial", J Clin Psychiatry, 72, pp.1054~1062 (2011)
  110. Gertsik L, "Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder", J Clin Psychopharmacol, 32, pp.61~64 (2012)
  111. Martins JG, "EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression : evidence from a meta-analysis of randomized controlled trials", J Am Coll Nutr, 28, pp.525~542 (2009)
  112. Bloch MH, "Omega-3 fatty acids for the treatment of depression : systematic review and meta-analysis", Mol Psychiatry, 17, pp.1272~1282 (2012)
  113. Martins JG, "Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder : a critique of Bloch and Hannestad and updated meta-analysis", Mol Psychiatry, 17, pp.1144~1149 (2012)
  114. Grosso G, "Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials", PLoS One, 9, pp.e96905~ (2014)
  115. Mocking RJ, "Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder", Transl Psychiatry, 6, pp.e756~ (2016)
  116. Bai ZG, "Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults : a systematic review and meta-analysis", J Affect Disord, 241, pp.241~248 (2018)
  117. Hallahan B, "Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression", Br J Psychiatry, 209, pp.192~201 (2016)
  118. Lin PY, "A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids", J Clin Psychiatry, 68, pp.1056~1061 (2007)
  119. Lin PY, "Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression", Mol Psychiatry, 17, pp.1161~1163 (2012)
  120. Appleton KM, "Omega-3 fatty acids for depression in adults", Cochrane Database Syst Rev, 2015, pp.CD004692~ (2015)
  121. Su KP, "Omega-3 polyunsaturated fatty acids for major depressive disorder", Expert Opin Investig Drugs, 22, pp.1519~1534 (2013)
  122. Su KP, "Personalized medicine with Omega-3 fatty acids for depression in children and pregnant women and depression associated with inflammation", J Clin Psychiatry, 76, pp.e1476~e1477 (2015)
  123. Chang CH, "Safety and tolerability of prescription omega-3 fatty acids : a systematic review and meta-analysis of randomized controlled trials", Prostaglandins Leukot Essent Fatty Acids, 129, pp.1~12 (2018)
  124. Su KP, "Nutrition, psychoneuroimmunology and depression : the therapeutic implications of omega-3 fatty acids in interferon-α-induced depression", Biomedicine(Taipei), 5, pp.21~ (2015)
  125. Song C, "The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease : acting separately or synergistically?", Prog Lipid Res, 62, pp.41~54 (2016)
  126. Li F, "Fish consumption and risk of depression : a meta-analysis", J Epidemiol Community Health, 70, pp.299~304 (2016)
  127. Liao Y, "Efficacy of omega-3 PUFAs in depression : a meta-analysis", Transl Psychiatry, 9, pp.190~ (2019)
  128. Guu TW, "International Society for Nutritional Psychiatry Research Practice Guidelines for omega-3 fatty acids in the treatment of major depressive disorder", Psychother Psychosom, 88, pp.263~273 (2019)
  129. Larqué E, "Omega 3 fatty acids, gestation and pregnancy outcomes", Br J Nutr., 107(Suppl 2), pp.S77~S84 (2012)
  130. Makrides M, "Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children : a randomized controlled trial", JAMA, 304, pp.1675~1683 (2010)
  131. Carlson SE, "DHA supplementation and pregnancy outcomes", Am J Clin Nutr, 97, pp.808~815 (2013)
  132. Shireman TI, "Docosahexaenoic acid supplementation(DHA)and the return on investment for pregnancy outcomes", Prostaglandins Leukot Essent Fatty Acids, 111, pp.8~10 (2016)
  133. de Seymour JV, "Omega-3 fatty acids to prevent preterm birth : Australian pregnant women's preterm birth awareness and intentions to increase omega-3 fatty acid intake", Nutr J, 18, pp.74~ (2019)
  134. Koletzko B, "Recommended nutrient intake levels for stable, fully enterally fed very low birth weight infants", World Rev Nutr Diet, 110, pp.297~299 (2014)

관련 논문AI추천

Dietary Reference Intake of n-3 polyunsaturated fatty acids for Koreans박용순한국영양학회 · Nutrition Research and Practice2022 · 제16권 제3호Polyunsaturated Fatty Acids in Children이지혁대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2013 · 제16권 제3호Dietary intake of n-3 and n-6 polyunsaturated fatty acids in Korean toddlers 12-24 months of age with comparison to the dietary recommendations김유진, 김혜숙, Oran Kwon한국영양학회 · Nutrition Research and Practice2019 · 제13권 제4호Association of dietary intake of total fat and fatty acids with the Omega-3 Index: a cross-sectional analysis of NHANES 2011–2012박용순, 진유리, 홍화진, Nathan L. Tintle, William S. Harris한국영양학회 · Nutrition Research and Practice2025 · 제19권 제1호Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders배치운, Kuan-Pin Su, Yutaka Matsuoka대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제2호Association between dietary omega-3 fatty acid intake and depression in postmenopausal women박경, Minjeong Chae한국영양학회 · Nutrition Research and Practice2021 · 제15권 제4호

이 간행물의 다른 논문 (9건)

Maternal high-fructose intake during pregnancy and lactation induces metabolic syndrome in adult offspring김인겸, Cho Hyun Min, Koo Soohyeon, Kim Minapp. 160-172Effects of the fermented Zizyphus jujuba in the amyloid β25-35-induced Alzheimer's disease mouse model조은주, Kim Hyun Young, KIM, MIN-JEONG, Jung Ji Eun, Lee Sanghyunpp. 173-186Feeding pattern, biochemical, anthropometric and histological effects of prolonged ad libitum access to sucrose, honey and glucose-fructose solutions in Wistar ratsRodríguez-Gudiño Juan José, Pineda-Lozano Jessica Elizabeth, Martínez Moreno Alma Gabriela, Virgen-Carrillo Carmen Alejandrinapp. 187-202Association between dietary branched-chain amino acid intake and skeletal muscle mass index among Korean adults: Interaction with obesityPark Hyoung Su, Chae Minjeong, Park Kyongpp. 203-212Nationwide “Pediatric Nutrition Day” survey on the nutritional status of hospitalized children in South KoreaChang Eun Jae, Chung Ju-Young, Choi So Yoon, Kim Soon Chul, Yi Dae Yong, Moon Kyung Rye, Lee Ji Hyuk, Kim Yong Joo, Yang Hye Ran, Kang Ben, Jang Hyo-Jeong, Kang Ki-Soo, Lee Yoon, Chang Ju Young, Lee Eun Hye, Lee Hae Jeong, Park Ji Sook, Kim Ju Young, Choi You Jin, Kim Hyun Jin, Lee Yoo Min, Ryoo Eell, Hong Jeana, Choe Byung Ho, Seo Ji-Hyunpp. 213-224
원문 보기